Current state of biologic pharmacovigilance in the European Union: improvements are needed. Issue 3 (4th March 2019)

• Record Type: Journal Article
• Authors: Felix, Thomas; Jordan, John B.; Akers, Catherine; Patel, Bina; Drago, Daniela
• Is Part Of: Expert opinion on drug safety. Volume 18:Issue 3(2019)
• Page Start: 231
• Page End: 240
• Publication Date: 2019-03-04
• Subjects: Adverse drug reactions -- biopharmaceuticals -- biosimilars -- pharmacovigilance; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2019.1577818
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Pharmacovigilance is essential to monitoring the safety profiles of authorized medicines. Compared with small-molecule drugs, biological drugs are more complex, more susceptible to structural variability due to manufacturing processes, and have the potential to induce immune-related reactions, underscoring the importance of safety monitoring for these products. Although highly similar to reference products, biosimilars are not expected to be structurally identical. For these reasons, proper reporting of potential adverse drug reactions (ADRs) using distinguishable names and batch numbers is essential for accurate tracing of all biological drugs. To address the need for robust pharmacovigilance, the European Parliament and Council of the European Union provided legislation regarding pharmacovigilance of biologics in 2010. Areas covered : This narrative review examines the current state of pharmacovigilance for biologics in the European Union (EU) and discusses relevant information on pharmacovigilance of biosimilars, the current EU pharmacovigilance system, and areas that could be improved. Expert opinion : Although steps have been taken to improve pharmacovigilance of biologics in the EU, several enhancements can still be made, including additional training for healthcare professionals on ADR reporting, the use of 2D barcodes that enhance traceability, and an open discussion of potentially missed opportunities in the pharmacovigilance of biosimilars.